Home › Liver Cancer (Hepatocellular Carcinoma) › Texas
Liver Cancer (Hepatocellular Carcinoma) clinical trials in Texas
50 studies for Liver Cancer (Hepatocellular Carcinoma) are looking for participants at sites in Texas.
Cities in Texas
A Study of ZW251 in Participants With Advanced Solid Tumors
- MD Anderson Cancer Center, Houston
- START San Antonio, San Antonio
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT07164313Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #46, Austin
- Exelixis Clinical Site #89, Dallas
- Exelixis Clinical Site #73, Irving
- and 2 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT05176483Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC
- Research Facility, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06726161National Liver Cancer Screening Trial
- UT Southwestern Medical Center and Parkland Hospital, Dallas
- Baylor College of Medicine, Houston
RecruitingPhase 4
Ages 18 to 85 · All sexes · Updated Sep 25, 2026 · NCT06084234A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- The University of Texas Md Anderson Cancer Center, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT06427941Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer
- M D Anderson Cancer Center, Houston
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Sep 14, 2026 · NCT04380545Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
- St. David's Medical Center, Austin
RecruitingObservational study
Ages 22 and older · All sexes · Updated Sep 11, 2026 · NCT06486454GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC
- University of Texas Southwestern, Harold C. Simmons Comprehensive Cancer Center, Dallas
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT04864054Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
- Research Site, Amarillo
- Research Site, Austin
- Research Site, Houston
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06921785THIO and Cadonilimab in Resectable Hepatocellular Carcinoma
- University of Texas Southwestern Medical Center, Dallas
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT07446257Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
- START San Antonio, San Antonio
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 27, 2026 · NCT06582017Adaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma
- University of Texas Southwestern Medical Center, Dallas
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT07689175Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
RecruitingPhase 1/2
12 Months – 30 Years · All sexes · Updated Aug 25, 2026 · NCT04851119Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
- START-San Antonio, San Antonio
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 24, 2026 · NCT06084481FOG-001 in Locally Advanced or Metastatic Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
- South Texas Accelerated Research Therapeutics, LLC, San Antonio
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT05919264First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
- Research Site, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 13, 2026 · NCT06795022A Study of MGC026 in Participants With Advanced Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
- University of Texas Health Science Center at Houston, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT06242470A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
- Clinical Trial Site, San Antonio
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 6, 2026 · NCT07749586A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Texas Oncology - West Texas, Amarillo
- Texas Oncology, P.A., Dallas
- Texas Oncology Gulf Coast, Pearland
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT06330064IDOV-Immune for Advanced Solid Tumors
- MD Anderson Cancer Center, Houston
- South Texas Accelerated Research Therapeutics, San Antonio
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT06910657A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Baylor Scott & White Research Institute, Dallas
- University of Texas MD Anderson Cancer Center, Houston
- Baylor Scott & White Medical Center, Temple
RecruitingPhase 2
Ages 8 and older · All sexes · Updated Jul 27, 2026 · NCT05503797A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- University of Texas Southwestern Medical Center - Simmons Cancer Center, Dallas
- UT Southwestern Medical Center - Redbird, Dallas
- Univ. of TX Southwestern Medical Center - Zale Lipshy University Hospital, Dallas
- and 8 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 22, 2026 · NCT05208762Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
- M D Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 16, 2026 · NCT05092373Multi-analyte Blood Test Clinical Trial
- South Texas Research Institute, Edinburg
- Texas Gastro Research, El Paso
- Impact Research Institute, Waco
RecruitingObservational study
Ages 18 and older · All sexes · Updated Jul 10, 2026 · NCT05199259CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules
- University of Texas Southwestern Medical Center, Dallas
Recruiting
Ages 18 and older · All sexes · Updated Jul 2, 2026 · NCT06184152A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
- Clinical Trial Site, Dallas
- Clinical Trial Site, Houston
- Clinical Trial Site, San Antonio
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 17, 2026 · NCT06600321Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
- VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX, Dallas
- Michael E. DeBakey VA Medical Center, Houston, TX, Houston
Recruiting
Ages 18 to 75 · All sexes · Updated Jun 17, 2026 · NCT05486572A Trial Utilizing 18F-FS PG PET to Guide Therapy in Hepatocellular Carcinoma
- The University of Texas M. D. Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 10, 2026 · NCT07116486A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
- The University of Texas MD Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 16 and older · All sexes · Updated Jun 2, 2026 · NCT07197554Short Stitch Versus Traditional Suture for the Prevention of Incisional Hernia After Open Hepatectomy
- M D Anderson Cancer Center, Houston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 26, 2026 · NCT04982653High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies
- M D Anderson Cancer Center, Houston
Recruiting
Ages 19 and older · All sexes · Updated May 22, 2026 · NCT05053555DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- USA13-0, Anderson
- USA12-0, Houston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 22, 2026 · NCT06953089A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
- Harold C. Simmons Comprehensive Cancer Center, Dallas
- University of Texas MD Anderson Cancer Center, Houston
- DHR Health Institute for Research and Development, McAllen
- and 1 more
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Apr 27, 2026 · NCT05440708Impact of "Teaching the Teachers" Concept on Global Education and Application of Hepatocellular Carcinoma Diagnosis Guidelines
- M D Anderson Cancer Center, Houston
RecruitingObservational studyHealthy volunteers welcome
All ages · All sexes · Updated Apr 15, 2026 · NCT05143619A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
- MD Anderson Cancer Center, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Apr 13, 2026 · NCT06362369Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
- Houston Methodist Hospital Cancer Center, Houston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Apr 2, 2026 · NCT05733598Evaluation of Resection Techniques for Pancreatic Tumors
- Methodist Dallas Medical Center, Dallas
RecruitingObservational study
Ages 18 and older · All sexes · Updated Mar 20, 2026 · NCT05128890Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
- Oncology Consultants, Houston
RecruitingPhase 1
Ages 18 to 65 · All sexes · Updated Mar 16, 2026 · NCT07176650Ligufalimab and Cadonilimab in Advanced Liver Cancers
- University of Texas Southwestern Medical Center, Dallas
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Feb 27, 2026 · NCT06789848Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma
- Baylor College of Medicine, Houston
RecruitingPhase 2
Ages 0 to 30 · All sexes · Updated Feb 24, 2026 · NCT04134559From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.